Anaritide (Auriculin-Registered Trademark) is a 25-amino-acid synthetic form of atrial natriuretic peptide. Scios Nova was developing anaritide acetate for use in the treatment, prevention and diagnosis of acute renal failure, heart failure and hypertension. Scios suspended development of AURICULIN® anaritide based upon the results of an interim analysis of data from a 250-patient Phase III study in oliguric acute renal failure. The study was suspended due to the low probability that a positive outcome could be obtained with respect to its primary clinical endpoint, dialysis-free survival.
Originator
Approval Year
PubMed
Sample Use Guides
Acute tubular necrosis: The patients received a 24-hour intravenous infusion of either anaritide (0.2 microgram per kilogram of body weight per minute)
Route of Administration:
Intravenous
In in vitro perfused hydronephrotic rat kidney model Anaritide completely reversed the NE-induced AA vasoconstriction with an IC50 of 9.3 +/- 5.6 nM. In contrast, ANP caused a further decrease in EA diameter at concentrations up to 10(-8) M, and elicited a slight dilation of the EA at 10(-7) M.
Subunit 0
|
|
INGREDIENT -> STARTING MATERIAL |
Showing 1 to 1 of 1 entries